Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial.
Phase of Trial: Phase III
Latest Information Update: 09 May 2011
At a glance
- Drugs Linezolid (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections
- Focus Therapeutic Use
- Sponsors Pfizer
- 09 May 2011 Actual end date changed from Feb 2006 to Jan 2006 as reported by ClinicalTrials.gov.
- 30 Aug 2006 Status change
- 10 Dec 2005 New trial record.